FluoGuide A/S Feed

Land	Danmark
Lista	First North Stockholm
Sektor	Hälsovård
Industri	Medicinteknik

2024-03-20 14:25:00 Minutes from Annual General Meeting in FluoGuide A/S -5,20% | 0,10 MDKK

2024-03-13 11:17:00 Chief Financial Officer (CFO) Ole Larsen buys shares +3,32% | 0,65 MDKK

2024-03-12 12:12:00 FluoGuide enters collaboration within robot assisted head and neck cancer surgery with Intuitive Surgical, a world leading robotic-assisted surgery company +12,68% | 0,98 MDKK

2024-03-01 12:41:00 Notice of Annual General Meeting in FluoGuide A/S -2,55% | 0,52 MDKK

2024-02-28 08:10:00 FluoGuide A/S publishes year-end and annual report for the fiscal year 2023 -5,24% | 0,34 MDKK

2024-02-23 16:02:00 FluoGuide A/S issues warrants to CFO +6,06% | 0,24 MDKK

2024-01-08 11:33:00 FluoGuide provides strategic update and outlines development plans towards commercialization of FG001 0,00% | 0,60 MDKK

2023-12-09 16:17:00 Chief Development Officer (CDO) Grethe Nørskov Rasmussen sells shares -6,38% | 1,61 MSEK

2023-12-08 09:55:00 FluoGuide raises SEK 12 million through exercise of warrants +0,58% | 2,65 MDKK

2023-11-29 08:00:00 FluoGuide A/S publishes interim report for the period January – September 2023 -3,77% | 1,08 MDKK

2023-11-13 08:35:00 FluoGuide announces FG001 meets primary endpoint in phase llb trial in aggressive brain cancer +0,24% | 0,79 MDKK

2023-11-06 10:01:00 FluoGuide confirms positive topline results from phase lla trial of FG001 in head & neck cancer at International Academy of Oral Oncology conference +0,92% | 1,18 MDKK

2023-10-03 10:34:00 FluoGuide receives FDA Orphan Drug Designation for FG001 in high-grade glioma +5,73% | 0,91 MDKK

2023-09-08 12:00:00 FluoGuide receives Danish award for the best share price performance since IPO -0,22% | 0,19 MDKK

2023-09-07 14:32:00 Positive interim data from phase lla trial of FG001 in head & neck cancer presented as a case report at the World Molecular Imaging Congress in Prague +4,77% | 0,54 MDKK

2023-08-30 08:05:00 FluoGuide A/S publishes interim report for the period January – June 2023 +1,09% | 0,50 MDKK

2023-08-29 09:32:00 FluoGuide reports further positive interim data from phase IIa trial of FG001 in head & neck cancer +6,73% | 0,38 MDKK

2023-08-28 16:15:00 FluoGuide completes patient enrollment and treatment in FG001 phase llb clinical trial in aggressive brain cancer -2,93% | 0,14 MDKK

2023-08-28 12:53:00 FluoGuide A/S issues warrants to the investors participating in the directed share issue -2,93% | 0,14 MDKK

2023-07-31 18:42:00 FluoGuide A/S issues warrants to Board members, management and employees -1,00% | 0,30 MDKK

2023-07-25 16:12:00 Minutes from Extraordinary General Meeting in FluoGuide A/S -2,76% | 3,56 MDKK

2023-07-07 13:35:00 FluoGuide convenes an extraordinary general meeting +0,24% | 0,06 MDKK

2023-07-05 13:33:00 FluoGuide completes a Directed Share Issue raising SEK 15 million -1,93% | 0,38 MDKK

2023-06-20 08:18:00 FluoGuide announces positive interim results from phase IIa trial of FG001 in head & neck cancer +5,12% | 0,55 MDKK

2023-06-07 09:00:00 FluoGuide announces positive topline results from phase IIa trial of FG001 in lung cancer +4,93% | 0,25 MDKK

2023-05-31 08:20:00 FluoGuide A/S publishes interim report for the period January – March 2023 -1,40% | 0,23 MDKK

2023-05-24 09:52:00 FluoGuide provides update on strong clinical trial progress +0,94% | 0,55 MDKK

2023-03-21 12:04:00 FluoGuide awarded prestigious grant together with two academic partners +1,00% | 0,71 MDKK

2023-03-21 11:47:00 Minutes from Annual General Meeting in FluoGuide A/S +1,00% | 0,71 MDKK

2023-03-06 22:27:00 Notice of Annual General Meeting in FluoGuide A/S -16,36% | 5,35 MDKK

2023-02-28 09:00:00 FluoGuide A/S publishes Year-end and annual report for the fiscal year 2022 +1,74% | 1,54 MDKK

2023-02-27 09:25:00 FluoGuide updates on recruitment in phase IIb aggressive brain cancer trial with FG001 -1,61% | 3,47 MDKK

2023-02-02 08:40:00 FluoGuide appoints Ole Larsen as CFO +2,05% | 0,39 MDKK

2023-01-25 13:50:00 CFO acquired shares in FluoGuide +1,98% | 0,60 MDKK

2023-01-09 10:30:00 FluoGuide releases positive interim result of FG001 in head and neck cancer +10,40% | 0,77 MDKK

2022-11-24 07:45:02 FluoGuide A/S publishes interim report for the period January – September 2022 -0,53% | 0,24 MDKK

2022-11-21 13:06:08 FluoGuide has enrolled the first patient in the phase IIa trial in head and neck cancer -4,00% | 0,35 MDKK

2022-11-08 08:33:49 FluoGuide reaches milestone with FG001 for phase III clinical supply -0,77% | 0,85 MDKK

2022-11-06 15:53:51 FluoGuide releases positive interim result of FG001-CT002, a phase IIa trial evaluating FG001 in patients with non-small cell lung cancer (NSCLC) undergoing surgery +3,59% | 2,05 MSEK

2022-10-20 12:07:39 FluoGuide has enrolled the first patient in the phase IIb trial in aggressive brain cancer -0,52% | 0,22 MDKK

2022-10-06 09:54:32 Presentation of phase l/lla clinical data of FG001 in aggressive brain cancer at the European Congress of Neurosurgery 2022 +25,12% | 0,56 MDKK

2022-10-03 13:01:34 The excellent phase I/IIa clinical data of FG001 in aggressive brain cancer was presented at the World Molecular Imaging Congress -3,24% | 0,19 MDKK

2022-09-06 13:46:36 FluoGuide has received approval from the Danish Medicines Agency to initiate phase II trial with FG001 in head and neck cancer -0,57% | 0,42 MDKK

2022-08-31 15:01:42 FluoGuide appoints new CFO -1,90% | 0,09 MDKK

2022-08-30 09:28:04 FluoGuide receives permission to start phase IIb trial in aggressive brain cancer +0,21% | 0,20 MDKK

2022-08-25 09:23:35 FluoGuide A/S publishes interim report for the period January – June 2022 -1,97% | 0,15 MDKK

2022-08-24 12:23:53 FluoGuide’s update on FG001’s clinical development +6,95% | 0,20 MDKK

2022-08-23 08:18:31 FluoGuide has submitted a Clinical Trial Application (CTA) to the Danish Medicines Agency to initiate phase II trial with FG001 in head and neck cancer -0,84% | 0,06 MDKK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

2025-02-27	Bokslutskommuniké 2024
2024-11-28	Kvartalsrapport 2024-Q3
2024-08-29	Kvartalsrapport 2024-Q2
2024-05-30	Kvartalsrapport 2024-Q1
2024-03-21	Ordinarie utdelning FLUO 0.00 DKK
2024-03-20	Årsstämma 2024
2024-02-28	Bokslutskommuniké 2023
2023-11-29	Kvartalsrapport 2023-Q3
2023-08-30	Kvartalsrapport 2023-Q2
2023-05-31	Kvartalsrapport 2023-Q1
2023-03-22	Ordinarie utdelning FLUO 0.00 DKK
2023-03-21	Årsstämma 2023
2023-02-28	Bokslutskommuniké 2022
2022-11-24	Kvartalsrapport 2022-Q3
2022-08-25	Kvartalsrapport 2022-Q2
2022-05-31	Kvartalsrapport 2022-Q1
2022-05-19	Ordinarie utdelning FLUO 0.00 DKK
2022-05-18	Årsstämma 2022
2022-03-30	Bokslutskommuniké 2021
2021-11-24	Kvartalsrapport 2021-Q3
2021-08-25	Kvartalsrapport 2021-Q2
2021-05-26	Kvartalsrapport 2021-Q1
2021-05-03	Ordinarie utdelning FLUO 0.00 DKK
2021-02-26	Bokslutskommuniké 2020
2021-02-09	Årsstämma 2021
2020-11-20	Kvartalsrapport 2020-Q3
2020-08-14	Kvartalsrapport 2020-Q2
2020-05-27	Kvartalsrapport 2020-Q1
2020-04-09	Ordinarie utdelning FLUO 0.00 DKK
2020-04-08	Årsstämma 2020
2020-02-28	Bokslutskommuniké 2019
2019-11-29	Kvartalsrapport 2019-Q3
2019-05-31	Kvartalsrapport 2019-Q1

FluoGuide A/S

Prenumeration

Kalender

Beskrivning

FluoGuide A/S

Prenumeration

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden